INTRODUCTION AND OBJECTIVES:
For provider organizations transitioning to value-based care models, physician engagement and support in testing new models is critical. Little is known about how to optimally engage physicians in these activities, which simultaneously target cost and quality of care. To test whether individualized physician feedback would improve adherence to a value-based care pathway, we gave quarterly surgeon-specific feedback on outcomes, practice patterns, and cost data. We hypothesized that value-based care pathway (VBCP) adherence would modestly increase.
METHODS: We studied men undergoing surgery for uncomplicated BPH at our institution between March 1, 2013 and December 17, 2015 . In April 2014, we defined and introduced a value-based care pathway (VBCP) for BPH to surgeons in our department. Physicians confidentially received their outcomes, cost, and practice pattern data compared to de-identified colleague data in a quarterly email from the Department leadership. Rates of pathway adherence were measured pre-and post-intervention. We used t-tests for physician-level evaluation using the physician as the unit of analysis. A multilevel logistic regression model was fit for patient-level analyses using random intercepts for the physician.
RESULTS: There were 225 patients with complete data available representing 18 treating urologists. Two value-based pathways were used for analysis. The AUA recommended pathway requires PSA testing when indicated, urinalysis, and post-void residual (PVR) measurement, but is silent on surgery type or preoperative invasive testing. The VBCP requires in addition that cystoscopy or urodynamics are not performed preoperatively and bipolar transurethral resection/vaporization is the operation of choice. In the physician-level analysis, AUA recommended compliance increased from 1.8% to 9.2% (p¼0.02) while increasing from 3.5% to 11.8% (p¼0.03) in the patient-level analysis.
VBCP compliance increased from 0% to 5% in physician-level (p¼0.002) and patient-level (p¼0.03) analyses.
CONCLUSIONS: Surgeon-specific data feedback, in isolation, very modestly drove physician behavior toward value-based care models for BPH surgery. VBCP adherence remained low throughout the study period. Further studies are needed to better understand whether physician-identified reporting of data or financial incentives might facilitate the transition to value-based care in urologic surgery. hospitals with excess readmission rates for certain targeted conditions. We aim to evaluate the effect of this program on targeted and nontargeted surgical conditions. METHODS: We used a 20% Medicare sample to identify readmissions following targeted (total hip arthroplasty, total knee arthroplasty) and non-targeted (cystectomy, abdominal aortic aneurysm repair, colectomy, lung resection) procedures from 2006 to 2014. Multivariable logistic regression was used to calculate adjusted readmission rates. Changes in hospital level readmission rates were analyzed for three distinct time periods (Pre, Measurement, Penalty) corresponding to the HRRP implementation timeline, using an interrupted time series approach. RESULTS: We identified 538,293 targeted and 165,432 nontargeted procedures performed at 2,779 hospitals. There was a significant decrease in the odds of readmission for all procedures, except cystectomy (Table) which also had the highest readmission rate at 27%. Prior to the policy, the readmission rate for non-targeted procedures was decreasing faster than that of targeted procedures (Figure) . However, this trend reversed during the Measurement period (difference in slope for targeted to non-targeted -0.10 [95% Confidence Interval -0.16 to -0.044]). Neither group had a significant change during the Penalty period.
Source of
CONCLUSIONS: While the HRRP effectively decreased readmissions for targeted surgery, there was no spillover benefit for nontargeted procedures. To decrease the burden of readmission after cystectomy, future efforts should focus on identifying the interventions that resulted in readmission reduction for targeted procedures and evaluating their effectiveness in this population.
Source of Funding: This work was supported by the American Cancer Society (RSG 12-323-01-CPHPS), the National Cancer Institute (R01 CA168691, R01 CA174768, T32 CA180984) and the National Institute on Aging (R01 AG048071). While there are numerous reports of constitutive Hedgehog/Gli activity in prostate cancer (PCa) cells, there is little evidence for a role of smoothened in this activity. Previously we showed that Gli proteins bind to full length-(FL-) and truncated-(t-) androgen receptors (ARs) at the N-terminal tau5 transactivation domain and that this binding co-activates AR transcriptional activity in PCa cells. Here we show, conversely, that transcriptionally active AR binds to a critical protein processing domain on Gli2/Gli3, alters their post-translational proteolytic processing and drives non-canonical Hedgehog signaling that facilitates androgen-independent growth of PCa cells.
METHODS: Site-specific mutations were introduced into the Gli2 C-terminal domain to identify the peptides involved in AR recognition. GST-pulldown was used to test binding of the mutated peptide to AR-tau5 peptide. Western blotting was used to quantify AR expression and the proteolytic states of Gli2 and 3 in LNCaP, LNCaP-AI, LN95 and VCaP cells. AR or Gli3 protein was knocked down with siRNAs. A Gliluciferase reporter was used to measure functional Gli activity in cells and qPCR was used to determine how AR or Gli expression manipulation affected expressions of endogenous Gli-responsive genes. Proximity ligation assays with antibodies against AR and Gli3 was used to quantify the relative binding of these proteins in androgen-dependent and androgen-independent cell lines.
RESULTS: Mutations in a repeat serine/arginine-rich peptide in the C-terminal domain of Gli2 (aa820-836) blocked Gli2 binding to AR. This peptide encompasses the Gli protein processing domain that regulates a site-specific proteolysis that renders transcriptionally active Gli proteins into transcriptional repressors. Binding of liganded AR to this site blocked Gli proteolysis and maintained Gli in transcriptionally active states. Knockdown of AR in androgen growth-independent cell lines induced proteolytic inactivation of Gli in PCa cells. Knockdown of Gli3 in these cells induced a loss of AR protein. Proximity ligation assays showed that binding between Gli3 and AR was higher in androgen-independent cell lines.
CONCLUSIONS: Transcriptionally active AR protein binding to Gli proteins protects both from a natural degradation process and provides a non-canonical means to activate Hedgehog signaling in PCa cells. Since Gli proteins regulate the expressions of growth-promoting genes, our findings suggest that the growth effects of androgens on PCa cells are the results of a non-canonical Hedgehog activation process.
